Renaissance Technologies LLC lessened its position in Harrow, Inc. (NASDAQ:HROW – Free Report) by 19.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 84,579 shares of the company’s stock after selling 20,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.23% of Harrow worth $2,982,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of HROW. Royal Bank of Canada raised its holdings in shares of Harrow by 102.5% in the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after purchasing an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Harrow by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after purchasing an additional 790 shares in the last quarter. Strs Ohio acquired a new stake in Harrow in the 1st quarter valued at $149,000. Legal & General Group Plc lifted its position in Harrow by 12.4% during the 2nd quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock worth $939,000 after buying an additional 3,384 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Harrow by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock worth $1,434,000 after buying an additional 3,994 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on HROW. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Monday, July 20th. Cantor Fitzgerald reduced their price target on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen downgraded Harrow from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Tuesday, July 21st. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.43.
Harrow Stock Performance
Shares of NASDAQ HROW opened at $40.44 on Friday. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a 12 month low of $28.54 and a 12 month high of $54.85. The stock has a 50 day moving average of $40.34 and a 200-day moving average of $40.12. The company has a market capitalization of $1.51 billion, a P/E ratio of -98.63 and a beta of 0.28.
Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The business had revenue of $44.20 million during the quarter, compared to the consensus estimate of $52.43 million. During the same quarter last year, the company posted ($0.38) EPS. As a group, equities research analysts predict that Harrow, Inc. will post 0.29 EPS for the current year.
Insider Activity
In related news, CFO Andrew R. Boll acquired 3,500 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were bought at an average cost of $29.90 per share, with a total value of $104,650.00. Following the completion of the transaction, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Adrienne L. Graves purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the purchase, the director owned 1,000 shares in the company, valued at $31,070. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. 12.80% of the stock is owned by corporate insiders.
Harrow Company Profile
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
See Also
- Five stocks we like better than Harrow
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW – Free Report).
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
